

The **VYVGART** Pregnancy Study



Interested to learn more about the observational VYVGART Pregnancy Study?

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy And/or Breastfeeding.

The Study was developed by argenx BV, the manufacturer of VYVGART® (efgartigimod alfa-fcab) and VYVGART HYTRULO®, (efgartigimod alfa and hyaluronidase-qvfc)*.

The pregnancy safety study is open to pregnant women who have received either VYVGART (efgartigimod alfa-fcab) or VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc).

This is a post-approval and non-interventional study. Please note that there is no available data on the use of efgartigimod during pregnancy. Safety and effectiveness in children is not established. Please refer to the efgartigimod Product labels for more information.



The
VYVGART
Pregnancy
Study

or visit www.clinicaltrials.gov (search for 'NCT06299748')
for more information